MK-0482
- Generic Name
- MK-0482
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- -
- Unique Ingredient Identifier
- -
- Background
MK-0482 is a novel humanized IgG4 monoclonal antibody targeting the immunoglobulin-like transcript (ILT) 3.
- Associated Conditions
- -
- Associated Therapies
- -
A Study to Evaluate MK-0482 for Relapsed/Refractory Acute Myeloid Leukemia (AML) or Chronic Myelomonocytic Leukemia (CMML) (MK-0482-002)
- Conditions
- Interventions
- First Posted Date
- 2021-09-09
- Last Posted Date
- 2024-12-11
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 13
- Registration Number
- NCT05038800
- Locations
- 🇮🇱
Hadassah Medical Center ( Site 0100), Jerusalem, Israel
🇮🇱Sheba Medical Center-Hemato Oncology ( Site 0101), Ramat Gan, Israel
🇺🇸University of Texas MD Anderson Cancer Center ( Site 0004), Houston, Texas, United States
KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Chemotherapy When Used With Investigational Agents in Treatment-naïve Participants With Stage IV Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/KEYMAKER-U01A)
- First Posted Date
- 2019-11-15
- Last Posted Date
- 2024-11-26
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 450
- Registration Number
- NCT04165070
- Locations
- 🇺🇸
Cleveland Clinic Main ( Site 0006), Cleveland, Ohio, United States
🇺🇸The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive C, Columbus, Ohio, United States
🇺🇸Abramson Cancer Center of the University of Pennsylvania ( Site 0010), Philadelphia, Pennsylvania, United States
KEYMAKER-U01 Substudy 3: Efficacy and Safety Study of Pembrolizumab (MK-3475) When Used With Investigational Agents in Participants With Advanced Non-small Cell Lung Cancer (NSCLC), Previously Treated With Anti-programmed Cell Death Receptor Ligand 1 (PD-L1) Therapy (MK-3475-01C/KEYMAKER-U01C)
- Conditions
- Interventions
- First Posted Date
- 2019-11-15
- Last Posted Date
- 2024-12-12
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 135
- Registration Number
- NCT04165096
- Locations
- 🇺🇸
Cleveland Clinic Main ( Site 0006), Cleveland, Ohio, United States
🇺🇸Banner MD Anderson Cancer Center ( Site 0001), Gilbert, Arizona, United States
🇺🇸City of Hope ( Site 0014), Duarte, California, United States
KEYMAKER-U01 Substudy 2: Efficacy and Safety Study of Pembrolizumab (MK-3475) When Used With Investigational Agents in Treatment-naïve Participants With Anti-programmed Cell Death Receptor Ligand 1 (PD-L1) Positive Advanced Non-small Cell Lung Cancer (NSCLC) (MK-3475-01B/KEYMAKER-U01B)
- Conditions
- Interventions
- First Posted Date
- 2019-11-15
- Last Posted Date
- 2024-11-18
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 120
- Registration Number
- NCT04165083
- Locations
- 🇺🇸
MedStar Franklin Square Medical Center ( Site 0033), Baltimore, Maryland, United States
🇺🇸Abramson Cancer Center of the University of Pennsylvania ( Site 0010), Philadelphia, Pennsylvania, United States
🇺🇸Massachusetts General Hospital ( Site 0003), Boston, Massachusetts, United States
A Study of MK-0482 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-0482-001)
- Conditions
- Interventions
- First Posted Date
- 2019-04-17
- Last Posted Date
- 2024-12-12
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 230
- Registration Number
- NCT03918278
- Locations
- 🇺🇸
Next Oncology ( Site 0001), San Antonio, Texas, United States
🇨🇦Princess Margaret Cancer Centre ( Site 0011), Toronto, Ontario, Canada
🇨🇦BC Cancer - Vancouver Center ( Site 0010), Vancouver, British Columbia, Canada
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.